These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24340348)

  • 1. Increased priority for regimens involving incretin-based and insulin therapy.
    Rodbard HW
    J Fam Pract; 2013 Dec; 62(12 Suppl CME):S5-11. PubMed ID: 24340348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In support of an early polypharmacy approach to the treatment of type 2 diabetes.
    Wright EE; Stonehouse AH; Cuddihy RM
    Diabetes Obes Metab; 2010 Nov; 12(11):929-40. PubMed ID: 20880339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incretin and incretin-based therapies].
    Harada N; Inagaki N
    Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating incretin-based therapies for population-based health care.
    Calabrese D
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.
    Nadeau DA
    Postgrad Med; 2010 May; 122(3):7-15. PubMed ID: 20463409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.
    Vora J; Bain SC; Damci T; Dzida G; Hollander P; Meneghini LF; Ross SA
    Diabetes Metab; 2013 Feb; 39(1):6-15. PubMed ID: 23022130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.